Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$27.51 - $27.51 $475,923 - $475,923
17,300 Added 41.59%
58,900 $1.62 Million
Q2 2024

Aug 15, 2024

SELL
$25.1 - $31.61 $4.44 Million - $5.59 Million
-177,000 Reduced 80.97%
41,600 $1.1 Million
Q1 2024

May 07, 2024

SELL
$30.27 - $43.79 $239,133 - $345,941
-7,900 Reduced 3.49%
218,600 $7.06 Million
Q4 2023

Feb 14, 2024

SELL
$31.31 - $44.19 $2.14 Million - $3.01 Million
-68,200 Reduced 23.14%
226,500 $9.54 Million
Q3 2023

Nov 14, 2023

BUY
$18.55 - $39.96 $2.48 Million - $5.33 Million
133,500 Added 82.82%
294,700 $11.3 Million
Q2 2023

Aug 11, 2023

BUY
$14.2 - $23.75 $631,900 - $1.06 Million
44,500 Added 38.13%
161,200 $3.06 Million
Q1 2023

May 16, 2023

BUY
$15.27 - $19.72 $175,605 - $226,780
11,500 Added 10.93%
116,700 $1.81 Million
Q4 2022

Feb 14, 2023

BUY
$6.59 - $17.75 $66,559 - $179,275
10,100 Added 10.62%
105,200 $1.87 Million
Q3 2022

Nov 14, 2022

SELL
$3.93 - $6.37 $76,242 - $123,578
-19,400 Reduced 16.94%
95,100 $531,000
Q2 2022

Aug 15, 2022

BUY
$3.38 - $5.65 $10,140 - $16,950
3,000 Added 2.69%
114,500 $447,000
Q1 2022

May 16, 2022

SELL
$5.06 - $8.77 $419,979 - $727,910
-83,000 Reduced 42.67%
111,500 $614,000
Q4 2021

Feb 14, 2022

SELL
$7.33 - $9.32 $1.76 Million - $2.24 Million
-240,600 Reduced 55.3%
194,500 $1.66 Million
Q3 2021

Nov 15, 2021

BUY
$7.01 - $11.37 $1.67 Million - $2.7 Million
237,700 Added 120.42%
435,100 $3.78 Million
Q2 2021

Aug 11, 2021

BUY
$9.4 - $16.85 $1.58 Million - $2.83 Million
168,000 Added 571.43%
197,400 $2.09 Million
Q1 2021

May 17, 2021

BUY
$13.08 - $49.6 $384,552 - $1.46 Million
29,400 New
29,400 $472,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.